Solna, Sweden. April 11th, 2012 -- At the annual Charing Cross vascular congress in London, April 14-18, Stille introduces the next generation of vascular imaging tables. The core technology of new imagiQ2 is based on new
proprietary, ultra transparent carbon fiber technology, which enables reduced dosing and improved
image quality in endovascular procedures.
Abdominal aortic aneurysm (AAA) ranks high among the most significant cardiovascular diseases in the
world. Every year, over 600,000 patients are diagnosed with the disease in the western world. The gold
standard has previously been to conduct open surgery to treat AAA patients. In the last 15 years endovascular
repair (EVAR) has quickly emerged as a widely accepted treatment for aortic aneurysms, with overall
penetration rates in the developed world reaching 30 percent. The total global market for endovascular AAA
repair procedures is valued at $2 billion and is expected to reach $3 billion by 2015.
Stille now introduces imagiQ2, the second generation vascular imaging table developed for procedures such
as endovascular repair of AAA. The new table is based on patented and proprietary technologies which
represents major innovation leaps in the imaging table industry.
Among the many new features, imagiQ2 includes a new patent pending, ultra transparent carbon fiber top that
offers the industry’s lowest attenuation which enables reduced dosing for clinicians and patients, improved
EVAR image quality and ultimately more efficient procedures.
”We’re now setting the new industry standards to improve patient safety and create more efficient
endovascular procedures. The new imagiQ2 is designed based on clear customer needs with pricing, safety
and features optimized for both in- and outpatient settings. imagiQ2 is the optimal C-arm complement in the
Hybrid OR.”, comments Philip Siberg, President and CEO of Stille.
imagiQ2 is the successor of imagiQ, Stille’s table that was introduced in the early 2000’s and now established
as the one of the leading endovascular imaging tables in the US, Japan and Europe. imagiQ has been a key
contributor to the technology shift from open to endovascular repair.
The new imagiQ2 is introduced as part of Stille’s new strategic plan that includes long-term goals to leverage
on the high-end mobile imaging table market. First customer shipments expected in Q3-Q4 of 2012.
For more information and pictures, meet imagiQ2 at www.stille.se/imagiQ2
Philip Siberg, President and CEO
Tel +46 70 7906734